New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
18:06 EDTKOOLCesca Therapeutics reports Q3 EPS (7c) vs. (7c) in Q313
Reports Q3 revenue $4.04M vs.4.9M. in Q313.
News For KOOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
06:09 EDTKOOLCesca Therapeutics files IDE application for no-option critical limb ischemia
Cesca Therapeutics has submitted an investigational device exemption application to the FDA for a pivotal multicenter study of the company's SurgWerks-CLI and VXP System for treating advanced stages of no-option lower limb critical limb ischemia. The IDE application is the result of two prior positive pilot and feasibility studies conducted in Italy and India, respectively, and collaborative pre-IDE feedback from the U.S. FDA. The primary endpoint is major amputation free survival at 12 months following enrollment.
November 13, 2014
16:02 EDTKOOLCesca Therapeutics reports Q1 EPS (8c), consensus (7c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use